Swathi Krishna Njarekkattuvalappil

Dr. Swathi Krishna Njarekkattuvalappil

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
YCYanjia Cao
Yanjia Cao
AKArun S Karthikeyan
Arun S Karthikeyan
KRKarthikeyan Ramanujam
Karthikeyan Ramanujam
RRReshma Raju
Reshma Raju
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
NLNathan C Lo
Nathan C Lo
Background: Typhoid fever remains a major public health problem in India. Recently, the Surveillance for Enteric Fever in India program completed a multisite surveillance study. However, data on subnational variation in typhoid fever are needed to guide the introduction of the new typhoid conjugate vaccine in India. Methods: We applied a geospatial statistical model to estimate typhoid fever incidence across India, using data from 4 cohort studies and 6 hybrid surveillance sites from October 2017 to March 2020. We collected geocoded data from the Demographic and Health Survey in India as predictors of typhoid fever incidence. We used a log linear regression model to predict a primary outcome of typhoid incidence. Results: We estimated a national incidence of typhoid fever in India of 360 cases (95% confidence interval [CI], 297–494) per 100 000 person-years, with an annual estimate of 4.5 million cases (95% CI, 3.7–6.1 million) and 8930 deaths (95% CI, 7360–12 260), assuming a 0.2% case-fatality rate. We found substantial geographic variation of typhoid incidence across the country, with higher incidence in southwestern states and urban centers in the north. Conclusions: There is a large burden of typhoid fever in India with substantial heterogeneity across the country, with higher burden in urban centers.

22 March 2024 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
HSHemant Deepak Shewade
Hemant Deepak Shewade
PSParth Sharma
Parth Sharma
RSRakesh Purushothama Bhat Suseela
Rakesh Purushothama Bhat Suseela
NSNandini Sharma
Nandini Sharma
Community Engagement (CE) for disease control and health has been tested for a long time across the globe for various health programmes. Realizing the need for true multisectoral action and CE and ownership for ending TB on an accelerated timeline, the Government of India launched a nationwide campaign for ‘TB Mukt Panchayat’ (meaning ‘TB free village council’ in Hindi language) on 24 March 2023, banking on the system of local self-governments in the country. Though it is an initiative with huge potential to contribute to India’s efforts to end the TB epidemic, it is not without a few shortcomings. We critically analyse the TB Mukt Panchayat initiative and suggest a few recommendations for the way forward.

1 January 2022 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
PRPriyanka Rajmohan
Priyanka Rajmohan
MJMaria Jose
Maria Jose
JTJoe Thomas
Joe Thomas
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
BABeena Antony
Beena Antony
PKPraveenlal Kuttichira
Praveenlal Kuttichira
Background: The reports on adverse experiences following vaccination are scanty from India. It is important to know the real-world post-vaccination experience outside of clinical trial conditions. Objectives: The study aims to estimate the incidence of adverse events following immunization with the ChAdOx1 nCoV-19 coronavirus vaccine and to identify the predictors for the development of vaccine adverse events. Methods: A prospective observational study was conducted among health care workers who received the ChAdOx1 nCoV-19 coronavirus vaccine. Study participants were monitored at the site for 30min following vaccination and were followed up for 7 days after receiving the second dose, with a purpose-specific designed online surveillance form to enquire about any adverse events following vaccination. We used the Chi-squared test for categorical variables and multivariate regression analysis to identify predictors for the development of vaccine adverse effects. Results: Of 411 participants, the mean age was 30.77 +/- 12.5 years and 76.2% were females. Overall, 207 (50.4%) respondents reported at least one post-vaccination symptom receiving either dose of coronavirus vaccination. Fever (34.8%), local pain at the injection site (28.0%), tiredness (25.5%), chills (20%), myalgia (18.7%), headache (17.8%), injection site stiffness (5.4%), joint pain (4.6%) and nausea-vomiting (3.8%) were the most prevalent symptoms following the first dose. Adverse reactions reported after the second dose were milder and less frequent. Post-vaccination symptoms were more likely in the younger age group, those with comorbidity particularly, bronchial asthma, and a history of allergy to food/drugs. Conclusion: All the adverse reactions were of a minor type and non-serious. Side effects were less common in older adults (>60 years). Reactions to the second dose were lesser in intensity and frequency. Younger age, history of allergy, and comorbidities, particularly asthma, were found to be major predictors for the development of adverse events and require more watchful vaccine administration.

1 March 2024 in International Journal of Public Health Science (IJPHS)
Verified
Journal Article
Open access
PDF file
MHMrudula Holkar
Mrudula Holkar
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
RSRohan Shah
Rohan Shah
RPRadhakishan Pawar
Radhakishan Pawar
SJSanjay Kamlakar Juvekar
Sanjay Kamlakar Juvekar
India carries the highest share of active and missing tuberculosis (TB) cases globally. The Government of India is prioritizing private sector engagement (PSE) in TB elimination activities, as most healthcare-seeking in the country happens in this sector. This study aimed to understand the knowledge and practices of private healthcare providers (PHP) on various aspects of TB case notification through the National TB Elimination Programme (NTEP). This cross-sectional study was carried out between Oct 2020 to April 2021 amongst PHPs in the Junnar Tuberculosis Unit (TU), Pune District, Maharashtra. Junnar Block has 299 PHPs who assess, diagnose, and/or treat TB cases. A total of 97 participants were enrolled in the study. About 89 (91.8%) PHPs are aware that TB case notifications are mandatory by law. However, 80.4% are unaware of the Ni-kshay portal (web-based case surveillance system) by NTEP. Similarly, 74 (76.3%) must be aware of incentives for PHPs to collaborate with the government healthcare delivery system. 82.8% of total Ayurveda, Unani, Naturopathy, Siddha, and Homeopathy (AYUSH) practitioners and 46.2% of Allopathic practitioners have poor knowledge about TB case notification, with a Chi-square value of 14.36 (p<0.01). Our study shows that the active engagement of private providers (PPs), especially AYUSH practitioners in rural areas, is a need of the hour in achieving TB elimination.

30 October 2023 in Viruses
Verified
Journal Article
Open access
PDF file
JTJoe Thomas
Joe Thomas
PRPriyanka Rajmohan
Priyanka Rajmohan
PJPonnu Jose
Ponnu Jose
RKRadhika Kannan
Radhika Kannan
RJRosmi Jose
Rosmi Jose
AGAlex George
Alex George
Background: Vaccine effectiveness for first-generation coronavirus disease (COVID-19) vaccines among People Living with HIV (PLHIV) in India remains unexplored. This study entails the estimation of the real-world effectiveness of COVID-19 vaccines (AZD1222/Covishield, BBV152/Covaxin) among PLHIV and the identification of variants of SARS-CoV-2 among those infected with COVID-19. Methods: An ambi-directional cohort study was conducted among 925 PLHIV above 18 years of age in two districts of central Kerala, India, from February 2022 to March 2023. Selected PLHIV were recruited as Participant Liaison Officers (PLOs) for the follow-up on the study participants. At enrolment, basic details, baseline CD4 count, and a Nasopharyngeal (NP) swab for RT-PCR were collected. In the follow-up phase, NP swabs were collected from subjects with COVID-19 symptoms. Positive subjects had a CD4 count and genomic sequencing performed. Results: The mean age of the participants was 46.93 ± 11.00 years. The majority, 819 (93.6%), of participants had received at least one dose of any vaccine, while 56 (6.4%) were unvaccinated. A total of 649 (79.24%) participants were vaccinated with Covishield and 169 (20.63%) with Covaxin. In the vaccinated group, 158 (19.3%) reported COVID-19 infection. Vaccine Effectiveness (VE) for one dose of any vaccine was 43.2% (95% CI: 11.8–64.5), p = 0.015. The effectiveness of full vaccination with Covishied was 63.8% (95% CI: 39.3–79.2), p < 0.001, and Covaxin was 73.4% (95% CI: 44.3–87.3). VE was highest, at 60.7% (95% CI: 23.6–81.3), when the two doses of the vaccine were given at an interval of less than 6 weeks. Participants with a baseline CD4 count > 350 had greater protection from COVID-19, at 53.4% (95% CI: 19.6–75.3) p = 0.004. The incident cases were sub-variants of Omicron (BA.2, BA.2.38, BA.2.10). Conclusions: Full vaccination with Covishield and Covaxin was effective against COVID-19 infection among PLHIV on treatment; albeit, that of Covaxin was higher. A gap of 4 to 6 weeks between the two doses of COVID-19 vaccine was found to have higher VE among PLHIV.

3 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
RBRamesh Bhaskaran
Ramesh Bhaskaran
SVSree Raj V
Sree Raj V
PJPonnu Jose
Ponnu Jose
ARAboobacker Mohammed Rafi
Aboobacker Mohammed Rafi
PKPraveenlal Kuttichira
Praveenlal Kuttichira
Background: India started Covid-19 vaccination from January 16, 2021 after the approval of two candidate vaccines namely Covishield ™ and Covaxin ™. We report antibody responses among healthcare workers following two doses of Covishield ™ vaccination in a tertiary care setting. Methods: This prospective serosurveillance study was done among healthcare workers of Jubilee Mission Medical College, vaccinated during January- March 2021. Blood samples were drawn from 170 participants after their 1 st dose and from 156 participants after their 2 nd dose of Covishield ™ to measure the specific Ig G antibodies against the recombinant S1 subunit of the S protein of SARS-CoV-2. Results: The median level of anti SARS CoV-2 Ig G antibody 28 days after the first dose vaccination is 3.64 S/C (IQR=5.91) and 11.6 S/C (IQR= 5.97) after 14 days of second dose vaccination. Protective levels of anti SARS CoV-2 Ig G antibodies is developed by 25 participants (14.7%) after 28 days of first dose of vaccination and by 109 participants (69.9%) after 14 days of second dose. 18-44 years age group (p=0.027) and absence of comorbidities (p=0.079) are associated with protective IgG levels. Conclusions: Rise in specific Ig G is observed after vaccination. Higher antibody response is observed with younger age group and absence of comorbidities, though statistically not significant. The influence of BMI is also not significant.